Skip Navigation LinksOA_ADAP_Management_Memo_2020-23_Removal_of_Crixivan_from_the_ADAP_Formulary

State of Cal Logo
EDMUND G. BROWN JR.
Governor

State of California—Health and Human Services Agency
California Department of Public Health


ADAP MM 2020-23
July 28, 2020


TO:
ADAP ENROLLMENT WORKERS

SUBJECT:
REMOVAL OF CRIXIVAN FROM THE ADAP FORMULARY

​ADAP MANAGEMENT MEMO 2020-23: REMOVAL OF CRIXIVAN FROM THE ADAP FORMULARY


Effective June 5, 2020, indinavir sulfate (Crixivan®) has been removed from the ADAP formulary. In March of 2020, ADAP received notification that the manufacturer of Crixivan®, an antiretroviral protease inhibitor, would cease production of the medication. The discontinuation is voluntary and not related to a safety, quality, or efficacy issue. As of May 2020, there is not a generic version of indinavir sulfate to maintain on the formulary; however, ADAP does have other protease inhibitors (e.g. atazanavir, darunavir, fosamprenavir, etc.) available through the formulary.

ADAP management requests that you share this information with your clinical leadership team and local prescribers. The ADAP drug formulary has been updated to reflect the removal of Crixivan®.  Access to the updated formulary is available at the following URL: https://cdph.magellanrx.com/member/documents.

If you have any questions regarding the addition of these medications to the ADAP formulary, please contact Cynthia Reed-Aguayo, ADAP Specialist, at (916) 449-5791.

Thank you,
Sandra_Robinson_E_Signature
Sandra Robinson, MBA
ADAP Branch Chief
California Department of Public Health





Page Last Updated :